Merck KGaA and Pfizer collaborate on lupus PMLiVE Currently most treatments available for SLE, typically corticosteroids, non-steroidal anti-inflammatory drugs and immunosuppresants, target the symptoms of the disease rather than its underlying pathology. The project between Merck, Pfizer and the ... |
